THE DIFFERENCE IS

PUTTING PRECISION
TO WORK

BD Advanced Glass Pre-Fillable Solutions for Biologics Drug Delivery

Wednesday, July 8, 2019
9 a.m. (EST) or 3 p.m. (CET)


What will you learn:


  • Who are we?
    BD Medical Pharmaceutical Systems – at a glance!


  • What market dynamics are creating new challenges for pharma and shaping delivery system requirements?
    Pharma and chronic disease market trends, opportunities and challenges leading to new requirements


  • How is BD raising the bar with advanced glass pre-fillable solutions for biotech?
    BD Neopak™ – Glass Pre-fillable Syringe platform - Turning experience into advanced solutions for biotech


  • What is the value of partnering with BD?
    Breakthrough technologies, global expertise, support and testing services, global manufacturing capabilities, prefillable expertise and support services at every stage including Regulatory and Medical Affairs.

Yes, I'd like to attend

Discovery. Diagnostics. Delivery.

Can be accessed on our Customer Learning Portal. The e-learning courses offer detailed and solution focused training to help better understand how to solve for common scenarios.

BD understands your needs


Placeholder

Experts from around the globe describe the intersection between patient and healthcare worker safety, focusing on techniques to improve both occupational and public health.

Webinar Objectives:

  • Describe the current global impact of bloodborne disease
  • Describe occupational exposure incidents for needlesticks and sharps injuries
  • Define safety as a function of focus for both patient and health worker, to reduce overall bloodborne disease
  • Provide guidance on the importance of prevention programs including use of safer medical devices, immunization/vaccination programs, and safe clinical practices
  • Illustrate an effective pathway for reporting exposure incidents and injuries
  • Define processes for post-exposure medical treatment and prophylaxis
  • Share global experiences from key stakeholders responsible for sharps safety and public health programs around the world

Save Your Seat

Discovery. Diagnostics. Delivery.

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Archit eos desgad eici omnit adias dis arcieni hilli perovit o c test eumquiam adi voluptias

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Video title here

Play

Major biologic manufacturers

representing up to 80% of the biologic market are using or testing BD Neopak™ Glass Prefillable Syringes*

*Based on BD internal sales (Vendavo 2017) and BD internal market model (InThought 2017)

At various viscosity levels,

our BD Neopak™ Glass Prefillable Syringe with autoinjector had a controlled injection time below 15 seconds with +/- 2 seconds variability*

*Neopak Injection Time” (internal study). Pont-de-Claix, FR: Becton Dickinson and Company, 2018

BD Neopak™ Glass Prefillable Syringes

displayed a 90% reject rate reduction compared to a standard prefillable syringe1

1Boehringer Ingelheim and Friedrich Haefele. Translating a QbD PFS into tangible value for Biopharmaceuticals. PDA. Universe of Pre-filled Syringes and Injection Devices. October 6–8, 2014.

BD NeopakTM with XsiTM silicone

Our immobilization technology can help you achieve up to 94% reduced particles vs conventional siliconized syringes*

   Interview with Sundeep Kankanala,
ONdrugDelivery >

*USP article 1802 ODD Issue_83

Our informative webinar is now available

Choice of device components in U.S. biosimilar combination products

Presenter: Alison Bascou
Sr. Regulatory Affairs Manager


This webinar provides an overview of the U.S. guidance for biosimilars. It examines case studies ranging from prefilled syringes to autoinjectors and safety devices, where biosimilars approved in additional, or “improved,” presentations are compared to reference presentations.


Webinar addresses key questions such as:


  • Can a biosimilar be approved in another presentation (autoinjector: AI) for the reference product (prefilled syringe [PFS] and vial)?


  • Does the biosimilar presentation need to be identical to that in the reference product?


  • What are the presentation considerations for interchangeability in the U.S.?


  • Can a new delivery device for a reference biologic increase exclusivity or patent production (lifecycle management)?

  • Can the biosimilar presentation be superior to the reference product?


Biosimilars are a growing topic in markets driven by health-cost concerns. Because biosimilars often target chronic diseases, there’s an increasing need for sophisticated delivery systems such as autoinjectors, which enable patients to self-inject. A key concern when developing a new biosimilar combination product is choosing the device component, which serves as both a container closure system for storage and a delivery device for administration.

Getting to market without delay can make all the difference in the success of your pipeline biosimilar or new drug. That’s why we’re dedicated to helping you take your drugs to market fast, and supporting your launch strategy by:

  • Mitigating risk with drug-container interactions
  • Anticipating combination product development requirements
  • Anticipating market demand expansion
  • Promoting effective life-cycle management

Our BD Neopak™ Prefillable Glass Syringe platform features:

  • A broad design space for agile development
  • A wide portfolio of options
  • Compatibility with BD safety and drug delivery systems
  • Unparalleled production capacity for glass prefillable syringes

Our robust integrated system approach facilitates development to support shorter time-to-market and reliable in-market performance. By choosing the BD Neopak™ Prefillable Glass Syringe portfolio, you are investing in a platform that’s uniquely supported by a wealth of data on extractables, biocompatibility stability, device compatibility and more—which you can leverage for your combination product development and registration. We can also offer you a full “container closure system” regulatory data package to help simplify your common technical document registration process.*

   When time to market is critical >
   Give tomorrow’s most demanding biotech drugs the strength of BD Neopak™ >
Discover a glass syringe with the data and reliability to help you find peace of mind throughout the drug development process >

*Case-by-case basis

Placeholder

Pellentesque habitant morbi

  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada

Placeholder

Pellentesque habitant morbi

  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Placeholder

As your partner throughout development, launch and beyond, we can support you with several key advantages:

  1. Deep expertise in prefillable drug delivery systems
  2. Expert consultation at every stage of drug development
  3. Regulatory expertise to support faster time to market
  4. Worldwide manufacturing to meet global production demands
  5. Comprehensive cross-functional support and dedicated teams
   Technical Services brochure >

   General Services Brochure >

Our BD Neopak™ Glass Prefillable Syringe platform offers you an advanced solution for biologic

Conceived for superior autoinjector compatibility

Minimizing drug-container interactions to ensure drug performance

Expanded design space with a broad portfolio

Adherence to strict quality requirements

Learn more about Neopak >

Hospitals and healthcare facilities

BD is a market leader in hospital products that can reduce the incidence of sharps injuries and exposure to bloodborne pathogens. Patient safety has been a focus of BD innovation for years, not only in the United States but also around the world. Working closely with organizations like the International Safety Center (EPINet) is an important part of our efforts to keep patients and workers safe.

Safety syringes and needles >>
Hazardous drug safety >>
Infection prevention >>

Hospitals and healthcare facilities

BD is a market leader in hospital products that can reduce the incidence of sharps injuries and exposure to bloodborne pathogens. Patient safety has been a focus of BD innovation for years, not only in the United States but also around the world. Working closely with organizations like the International Safety Center (EPINet) is an important part of our efforts to keep patients and workers safe.

Safety syringes and needles >>
Hazardous drug safety >>
Infection prevention >>

Uscid est ad quis et lam sitatium commoloribus solupta illaborum doloria alisci dioribus si quis porereh enianimus mollam, quo maxim quis ma senimus, alit,Deles etusapici am, inusdae commodi cupiderro doluptas acipsap elignatio omnihilla inihiliciu Denihit doluptamus ut ped ut eatinie ndandem. Quae. Olut exerios dipsum nis

E-learning courses

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

User group webcasts

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Let's have a conversation

E-learning courses
User group webcasts

Let's have a conversation

E-learning courses
User group webcasts

Let's have a conversation

Ibus exped et ape

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Let's have a conversation

REFERENCES

1. Jones M.Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

2. CDC Laboratory quality assurance and standardization programs December 1,2014

BD is committed to keeping your personal data protected and secure. More information on how we protect your personal data can be found in our privacy statement and our cookie policy.

Contact us | Unsubscribe | My profile